Department of Life Sciences and Health, Faculty of Health Sciences, Oslo Metropolitan University, St. Olavs Plass, P.O. Box 4, N-0130, Oslo, Norway.
Glycoconj J. 2024 Oct;41(4-5):323-342. doi: 10.1007/s10719-024-10165-8. Epub 2024 Sep 17.
The intestinal barrier is a selective interface between the body´s external and the internal environment. Its layer of epithelial cells is joined together by tight junction proteins. In intestinal permeability (IP), the barrier is compromised, leading to increased translocation of luminal contents such as large molecules, toxins and even microorganisms. Numerous diseases including Inflammatory Bowel Disease (IBD), Coeliac disease (CD), autoimmune disorders, and diabetes are believed to be associated with IP. Dietary interventions, such as prebiotics, may improve the intestinal barrier. Prebiotics are non-digestible food compounds, that promote the growth and activity of beneficial bacteria in the gut. This systematic review assesses the connection between prebiotic usage and IP. PubMed and Trip were used to identify relevant studies conducted between 2010-2023. Only six studies were found, which all varied in the characteristics of the population, study design, and types of prebiotics interventions. Only one study showed a statistically significant effect of prebiotics on IP. Alteration of intestinal barrier function was measured by lactulose/mannitol, chromium-labelled Ethylenediaminetetraacetic acid (Cr-EDTA), lactulose/rhamnose, and sucralose/erythritol excretion as well as zonulin and glucagon-like peptide 2 levels. Three studies also conducted gut microbiota assessment, and one of them showed statistically significant improvement of the gut microbiome. This study also reported a decrease in zonulin level. The main conclusion from this review is that there is a lack of human studies in this important field. Futhermore, large population studies and using standardized protocols, would be required to properly assess the impact of prebiotic intervention and improvement on IP.
肠道屏障是机体内外环境之间的选择性界面。其上皮细胞层由紧密连接蛋白连接。在肠道通透性(IP)中,屏障受损,导致腔内内容物(如大分子、毒素甚至微生物)的易位增加。许多疾病,包括炎症性肠病(IBD)、乳糜泻(CD)、自身免疫性疾病和糖尿病,都被认为与 IP 有关。饮食干预,如益生元,可能改善肠道屏障。益生元是不可消化的食物化合物,可促进肠道中有益细菌的生长和活性。本系统评价评估了益生元使用与 IP 之间的关系。使用 PubMed 和 Trip 检索了 2010 年至 2023 年期间进行的相关研究。仅发现了六项研究,这些研究在人群特征、研究设计和益生元干预类型方面均存在差异。只有一项研究显示益生元对 IP 有统计学意义的影响。肠道屏障功能的改变通过乳果糖/甘露醇、铬标记乙二胺四乙酸(Cr-EDTA)、乳果糖/鼠李糖和蔗糖/赤藓糖醇排泄以及紧密连接蛋白和胰高血糖素样肽 2 水平来测量。三项研究还进行了肠道微生物组评估,其中一项研究显示肠道微生物组有统计学意义的改善。该研究还报告了紧密连接蛋白水平的降低。本综述的主要结论是,在这个重要领域缺乏人类研究。此外,需要进行大规模人群研究并使用标准化方案,以正确评估益生元干预和改善对 IP 的影响。